The Human Immune Monitoring Center (HIMC) Shared Resource provides state-of-the-art assays that measure biomarkers relevant to the immune system or specific pathogens. Examples of biomarkers that are specifically relevant to cancer include changes in lymphocyte signaling pathways, serum cytokines, and specific immune responses that target tumor cells. This resource offers Cancer Center members specialized assays that monitor the effects and efficacy of immunotherapies and vaccination strategies that are becoming increasingly important alternatives or adjuvants to conventional forms of cancer treatment. In addition, pathogens have been implicated in the etiology of many cancers, and the HIMC offers array methodologies for pathogen identification. The HIMC initiated operations in early 2007, and has attracted many faculty users in the past two years;74% of the current users are Cancer Center members. We expect an increasing demand for our services as new projects and clinical trials in the immune modulation of cancer are developed. Major services provided by the HIMC are Luminex bead-based assays for measuring cytokines, FACS phenotyping and phosphoflow analysis for cell characterization, and the Firefly nanofluidics assay method for detecting phosphorylated proteins. Dr. Holden Maecker is the Facility Director of HIMC and an expert in cancer immunology and immune monitoring. Leadership is provided by Dr. Maecker and oversight is provided by the HIMC Advisory Committee, consisting of 10 faculty and headed by Dr. Mark Davis, who is an internationally known expert in lymphocyte recognition and immune monitoring technologies. He is also the principal inventor of the peptide-MHC tetramer technology to monitor specific T cell responses. Future goals of the HIMC are to introduce for general use the multiplex peptide-MHC tetramer technology recently developed by the Davis lab to quantitate and characterize T cell responses to tumor associated antigens and the complementary ELISPOT analysis, which quantitates T and B cell responses. The shared resource will also offer full bioinformatics consulting and data management for its users.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-07
Application #
8475466
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$75,786
Indirect Cost
$3
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Lee, Bee L; Fan, Shenghua K; Lu, Ying (2017) A curve-free Bayesian decision-theoretic design for two-agent Phase I trials. J Biopharm Stat 27:34-43
Mohanty, Suchismita; Chen, Zixin; Li, Kai et al. (2017) A Novel Theranostic Strategy for MMP-14-Expressing Glioblastomas Impacts Survival. Mol Cancer Ther 16:1909-1921
Alcántara-Hernández, Marcela; Leylek, Rebecca; Wagar, Lisa E et al. (2017) High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization. Immunity 47:1037-1050.e6
Chao, Mark P; Gentles, Andrew J; Chatterjee, Susmita et al. (2017) Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell 20:329-344.e7
Rogers, Zoë N; McFarland, Christopher D; Winters, Ian P et al. (2017) A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods 14:737-742
Sun, Ruping; Hu, Zheng; Sottoriva, Andrea et al. (2017) Between-region genetic divergence reflects the mode and tempo of tumor evolution. Nat Genet 49:1015-1024
Jin, Yuxue; Lai, Tze Leung (2017) A new approach to regression analysis of censored competing-risks data. Lifetime Data Anal 23:605-625
Clarke, Christina A; Glaser, Sally L; Leung, Rita et al. (2017) Prevalence and characteristics of cancer patients receiving care from single vs. multiple institutions. Cancer Epidemiol 46:27-33
Han, Summer S; Ten Haaf, Kevin; Hazelton, William D et al. (2017) The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. Int J Cancer 140:2436-2443
Wender, Paul A; Hardman, Clayton T; Ho, Stephen et al. (2017) Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV. Science 358:218-223

Showing the most recent 10 out of 227 publications